Prevalence and outcomes of concomitant cardiac amyloidosis and coronary artery disease

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology Pub Date : 2024-11-24 DOI:10.1016/j.cpcardiol.2024.102932

Koyenum Obi MD , Sahil Bharwani DO MPH , Vince Catalfamo MD , Antonio Duran MD , Harith Baldawi MD , Connor Gillies DO , Senthil Anand MBBS , James Wever-Pinzon MD , Clement Eiswirth MD , Sapna Desai MD , Selim Krim MD

{"title":"Prevalence and outcomes of concomitant cardiac amyloidosis and coronary artery disease","authors":"Koyenum Obi MD , Sahil Bharwani DO MPH , Vince Catalfamo MD , Antonio Duran MD , Harith Baldawi MD , Connor Gillies DO , Senthil Anand MBBS , James Wever-Pinzon MD , Clement Eiswirth MD , Sapna Desai MD , Selim Krim MD","doi":"10.1016/j.cpcardiol.2024.102932","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cardiac amyloidosis (CA) and coronary artery disease (CAD) can have similar presentations in the acute care setting which can potentially delay the diagnosis of CA.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of patients referred to our institution for evaluation of cardiac amyloidosis. We obtained demographic and clinical characteristics, laboratory data, and echocardiographic measurements of those patients with confirmed cardiac amyloidosis. The population was divided into two groups based on the presence of CAD. Frequency of heart failure hospitalizations, and one-year overall mortality were compared between both groups.</div></div><div><h3>Results</h3><div>Between 2018 to 2021, 327 patients with suspected cardiac amyloidosis were referred to our institution. Out of 114 confirmed CA patients, 28 patients (25%) had concomitant CAD and CA. The overall mean age of CA diagnosis was 74.7 (±8.4) years for the CAD group and 69.7 (±9.8) for the non-CAD group (P value 0.002). Notably, a higher percentage of males were observed in the CAD group (92/.9% vs. 60%, p-value 0.002), and a higher prevalence of hypertension (92.9% vs 70%, p-value 0.018) and dyslipidemia (89.3% vs 59%, p-value 0.004) were also found in the CAD group. Overall, there were no significant differences in outcomes.</div></div><div><h3>Conclusion</h3><div>Larger studies are needed to identify characteristics that will result in a prompt diagnosis of CA in patients with concomitant CAD. Although our study did not appreciate a significant difference between these two groups, outcomes of our study were likely impacted by a small sample size in the CA with CAD cohort.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 2","pages":"Article 102932"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S014628062400567X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cardiac amyloidosis (CA) and coronary artery disease (CAD) can have similar presentations in the acute care setting which can potentially delay the diagnosis of CA.

Methods

We conducted a retrospective analysis of patients referred to our institution for evaluation of cardiac amyloidosis. We obtained demographic and clinical characteristics, laboratory data, and echocardiographic measurements of those patients with confirmed cardiac amyloidosis. The population was divided into two groups based on the presence of CAD. Frequency of heart failure hospitalizations, and one-year overall mortality were compared between both groups.

Results

Between 2018 to 2021, 327 patients with suspected cardiac amyloidosis were referred to our institution. Out of 114 confirmed CA patients, 28 patients (25%) had concomitant CAD and CA. The overall mean age of CA diagnosis was 74.7 (±8.4) years for the CAD group and 69.7 (±9.8) for the non-CAD group (P value 0.002). Notably, a higher percentage of males were observed in the CAD group (92/.9% vs. 60%, p-value 0.002), and a higher prevalence of hypertension (92.9% vs 70%, p-value 0.018) and dyslipidemia (89.3% vs 59%, p-value 0.004) were also found in the CAD group. Overall, there were no significant differences in outcomes.

Conclusion

Larger studies are needed to identify characteristics that will result in a prompt diagnosis of CA in patients with concomitant CAD. Although our study did not appreciate a significant difference between these two groups, outcomes of our study were likely impacted by a small sample size in the CA with CAD cohort.

查看原文本刊更多论文

心脏淀粉样变性和冠状动脉疾病并发症的发病率和预后。

背景：心脏淀粉样变性（CA）和冠状动脉疾病（CAD）在急诊中的表现相似，可能会延误CA的诊断：心脏淀粉样变性（CA）和冠状动脉疾病（CAD）在急性期的表现相似，这可能会延误CA的诊断：我们对转诊至本机构评估心脏淀粉样变性的患者进行了回顾性分析。我们获得了确诊为心脏淀粉样变性患者的人口统计学特征、临床特征、实验室数据和超声心动图测量结果。根据是否患有 CAD 将患者分为两组。比较两组患者的心力衰竭住院频率和一年总死亡率：2018年至2021年间，327名疑似心脏淀粉样变性患者转诊至我院。在114名确诊的CA患者中，28名患者（25%）同时患有CAD和CA。CAD组确诊CA的总平均年龄为74.7（±8.4）岁，非CAD组为69.7（±9.8）岁（P值0.002）。值得注意的是，CAD 组中男性比例较高（92/.9% 对 60%，P 值 0.002），高血压（92.9% 对 70%，P 值 0.018）和血脂异常（89.3% 对 59%，P 值 0.004）发生率也较高。总体而言，结果无明显差异（表 1）：结论：需要进行更大规模的研究，以确定哪些特征可使合并有 CAD 的患者被及时诊断为 CA。虽然我们的研究没有发现这两组患者之间存在显著差异，但我们的研究结果可能会受到伴有 CAD 的 CA 组样本量较小的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Problems in Cardiology 医学-心血管系统

CiteScore

4.80

自引率

2.40%

发文量

392

审稿时长

6 days

期刊介绍： Under the editorial leadership of noted cardiologist Dr. Hector O. Ventura, Current Problems in Cardiology provides focused, comprehensive coverage of important clinical topics in cardiology. Each monthly issues, addresses a selected clinical problem or condition, including pathophysiology, invasive and noninvasive diagnosis, drug therapy, surgical management, and rehabilitation; or explores the clinical applications of a diagnostic modality or a particular category of drugs. Critical commentary from the distinguished editorial board accompanies each monograph, providing readers with additional insights. An extensive bibliography in each issue saves hours of library research.